Event-driven trading is the discipline of identifying and positioning ahead of specific, knowable events that will materially affect a stock's price. The edge is not in predicting the outcome — it is in identifying the event earlier, understanding the setup more completely, and managing the position more systematically than other participants.
Not every event creates a tradeable opportunity. The ones that do share a common set of characteristics: they are knowable in advance, they have a defined timeline, they are material to the stock's value, and they are not fully priced in by the time a systematic trader can identify them.
The categories that consistently generate event-driven opportunities in small and micro-cap stocks:
Every event-driven position goes through the same lifecycle, and the tools you use at each stage determine whether you capture the opportunity or watch it from the sideline.
The first stage is finding the event before it is widely known. For biotech catalysts, that means monitoring NDA acceptance announcements and FDA calendar publications. For supply chain opportunities, it means having the relationship data mapped before the customer's earnings date appears on the calendar. Tools like BiotechSigns (for FDA events) and ChainSifter (for supply chain relationships) automate this identification across hundreds of companies simultaneously.
Identifying the event is necessary but not sufficient. A PDUFA date with no cash runway, an active ATM offering program, and three analyst price targets already priced at approval is a very different setup than the same PDUFA with 18 months of cash, no dilution, and a market cap implying only 10% probability of approval. Small-cap trading tools that combine the catalyst calendar with dilution risk data provide this multi-layer setup analysis.
Event-driven positions should be sized relative to the probability of the event, the magnitude of the expected move, and the timeline to resolution. A PDUFA in 90 days with defined binary outcomes allows for larger initial sizing than an unspecified "data readout sometime in 2026" with undefined timing. Positions entered closer to a known event date typically carry less calendar risk but also offer less runway for the thesis to develop.
Active monitoring during the event window is critical. New filings, unexpected FDA communications, and changes in the company's capital structure can all materially change the risk/reward calculation before the event resolves. Automated filing alerts ensure that you learn about material developments the same day they become public — not days later when the stock has already moved.
The resolution of a catalyst event is itself information about the next trade. When a drug approval is followed immediately by a secondary offering, it signals that management was waiting for the approval to raise capital. When a contract award announcement is buried in a procurement database rather than a press release, it may indicate the company doesn't yet recognize the significance of the contract — creating an opportunity before management highlights it on the next earnings call.
Professional event-driven traders maintain a forward-looking pipeline of events by quarter — not just for companies they own but for the full universe of names they monitor. This pipeline answers the question: what material events are coming in the next 30, 60, and 90 days, and which of them are set up for entry?
Building this pipeline manually requires aggregating information from multiple sources: the FDA calendar, clinical trial registries, regulatory filing search tools, and procurement databases. Automated tools that maintain this pipeline continuously — updating as new events are disclosed and removing events that have resolved — are what allow event-driven traders to operate at scale across a broad universe.
The TraderTools Pro research stack is designed around this pipeline model: BiotechSigns maintains the catalyst calendar, DilutionWatch provides the dilution context, and ChainSifter surfaces the supply chain relationships that create the secondary event opportunities.
The most common mistake in event-driven trading is treating the event itself as the exit signal rather than a waypoint in the position lifecycle. An FDA approval followed by a secondary offering is a different exit than an approval followed by clean institutional buying. The exit strategy should be defined before entry — not improvised after the event resolves.
Position limits for binary events, defined stop-losses based on filing triggers (not just price), and systematic review of the dilution picture every quarter are the three non-negotiable components of an event-driven risk management process.
Event-driven trading positions around specific, knowable future events — FDA decisions, contract awards, earnings releases, regulatory filings — rather than chart patterns or price momentum. The edge comes from identifying events before they are widely priced in and understanding the setup more completely than other participants. Technical trading uses past price and volume patterns to predict future price movement. Event-driven traders often use both: technical levels to optimize entry timing within an event-driven setup.
Biotech PDUFA dates are known 10-12 months in advance. Government contract renewal cycles are often predictable based on contract end dates. Supply chain catalyst events tied to a major customer's earnings date are known weeks in advance. Filing-triggered events (prospectus supplements, material agreements) can appear without warning, which is why real-time filing surveillance is a prerequisite rather than an enhancement for event-driven traders.
The minimum viable toolkit for event-driven small-cap trading includes: (1) a real-time regulatory filing alert system covering all watchlist companies, (2) a catalyst calendar updated automatically from verified sources, (3) dilution surveillance showing current shelf status and warrant counts, and (4) cash runway estimates for development-stage companies. TraderTools Pro covers all four in one subscription.
Position sizing for event-driven trades should reflect three factors: the probability of the event resolving favorably, the magnitude of the expected move, and the timeline to resolution. A binary biotech event with a 30% historical base rate of approval might warrant a smaller initial position than a supply chain catalyst with clearer fundamental support. Most event-driven traders size initial positions at 1-3% of portfolio for binary events and scale up only with confirming signals closer to the event date.
The biggest risk is not a negative event outcome — it is unexpected dilution that fundamentally changes the risk/reward calculation during the event window. A company that files an ATM offering agreement while you are holding a position into a PDUFA date has changed the game: now you face dilution risk on top of binary event risk. Real-time filing alerts that catch these mid-position changes are the most underappreciated risk management tool in event-driven trading.